Evidence map›Paper›PMID 34089425›Full record

ArticleJournal, genetic engineering & biotechnology2021

Impact of circulating miRNA-373 on breast cancer diagnosis through targeting VEGF and cyclin D1 genes.

Noha M Bakr, Magda Sayed Mahmoud, Reem Nabil, Hussein Boushnak, Menha Swellam

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal, genetic engineering & biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Noha M BakrBiochemistry Department, Genetic Engineering and Biotechnology Research Division, National Research Centre, Dokki, Giza, 12622, Egypt. noni_mb@yahoo.com.ORCID http://orcid.org/0000-0002-0485-7138
Magda Sayed MahmoudBiochemistry Department, Genetic Engineering and Biotechnology Research Division, National Research Centre, Dokki, Giza, 12622, Egypt.
Reem NabilClinical Pathology Department, National Cancer Institute, Cairo, Egypt.
Hussein BoushnakSurgery Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Menha SwellamBiochemistry Department, Genetic Engineering and Biotechnology Research Division, National Research Centre, Dokki, Giza, 12622, Egypt.
National Research Centre · EGAin Shams University · EGChildren Cancer Hospital · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBreast cancer (BC) is the common primary tumor among females. Hence, there is an urgent need to improve the early prediction and diagnosis of BC. For that reason, the object of the current study is to analyze the expression levels of miRNA-373 and its target genes including vascular endothelial growth factor (VEGF) and cyclin D1 in women with BC.

resultsUpregulation of miRNA-373 and its target genes was observed in BC patients followed by patients with benign breast lesions compared to downregulation in controls. There was a significant association between the expression level of miRNA-373 and all clinical features. The same associations were observed between its target genes and all clinico-pathological features except hormonal status. The correlation between miRNA-373 and both genes was significant.

conclusionsOur results prove that miRNA-373, as an oncomir, would be a vital biomarker for BC diagnosis and prognosis by targeting both VEGF and cyclin D1.

Indexed as

Breast cancerClinico-pathological characteristicsCyclin D1DiagnosisMicroRNAVEGF

Identifiers

PMID34089425
PMCPMC8179880
OpenAlexW3165195430

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.